Dr. Edmund Kostewicz

Johann Wolfgang University, Institute of Pharmaceutical Technology, Germany

Senior researcher within the Institute of Pharmaceutical Technology at Johann Wolfgang University Germany

Supervisor of ESR8

Background

Edmund Kostewicz received a BSc. from the University of Adelaide (Australia), his Honours Degree was awarded at Flinders University (Australia) and his PhD from the University of South Australia (Australia).

Following completion of his PhD, he held a Post Doc position in the Institute for Pharmaceutical Technology at the Goethe University (Germany). He then took up a position as Research Scientist within the Department of Biopharmaceutics at AstraZeneca (Sweden) and then as Project Coordinator within the Centre for Drug Candidate Optimisation at Monash University in Melbourne (Australia). Edmund has held his current position in the Institute for Pharmaceutical Technology at Goethe University since 2009.

His research interests focus on tools for predicting oral drug absorption in humans. In doing so, Edmund Kostewicz conducts applied research using in vitro and in silico models to predict oral drug absorption in humans, in vivo prediction of gastrointestinal (GI) absorption using the transfer model and use of physiologically based pharmacokinetic modelling to simulate drug absorption.

Selected Publications

  • Pettarin M, Bolger MB, Chronowska M, Kostewicz ES. A combined in vitro in-silico approach to predict the oral bioavailability of borderline BCS Class II/IV weak base albendazole and its main metabolite albendazole sulfoxide. Eur J Pharm Sci. 2020;155:105552.
  • Pathak SM, Ruff A, Kostewicz ES, Patel N, Turner DB, Jamei M. Model-Based Analysis of Biopharmaceutic Experiments To Improve Mechanistic Oral Absorption Modeling: An Integrated in Vitro in Vivo Extrapolation Perspective Using Ketoconazole as a Model Drug. Mol Pharm. 2017;14:4305–20.
  • Kostewicz ES, Abrahamsson B, Brewster M, Brouwers J, Butler J, Carlert S, et al. In vitro models for the prediction of in vivo performance of oral dosage forms. Eur J Pharm Sci. 2014;57:342–66.
  • Litou C, Patel N, Turner DB, Kostewicz E, Kuentz M, Box KJ, Dressman J. Combining biorelevant in vitro and in silico tools to simulate and better understand the in vivo performance of a nano-sized formulation of aprepitant in the fasted and fed states. Eur J Pharm Sci. 2019;138:105031.
  • Ruff A, Fiolka T, Kostewicz ES. Prediction of Ketoconazole absorption using an updated in vitro transfer model coupled to physiologically based pharmacokinetic modelling. Eur J Pharm Sci. 2017;100:42–55. doi:10.1016/j.ejps.2016.12.017.
  • Pepin XJH, Dressman J, Parrott N, Delvadia P, Mitra A, Zhang X, et al. In Vitro Biopredictive Methods: A Workshop Summary Report. J Pharm Sci. 2021;110:567–83.
  • O’Dwyer PJ, Litou C, Box KJ, Dressman JB, Kostewicz ES, Kuentz M, Reppas C. In vitro methods to assess drug precipitation in the fasted small intestine – a PEARRL review. J Pharm Pharmacol. 2019;71:536–56.
  • Litou C, Turner DB, Holmstock N, Ceulemans J, Box KJ, Kostewicz E, et al. Combining biorelevant in vitro and in silico tools to investigate the in vivo performance of the amorphous solid dispersion formulation of etravirine in the fed state. Eur J Pharm Sci. 2020;149:105297.
  • Kostewicz ES, Aarons L, Bergstrand M, Bolger MB, Galetin A, Hatley O, et al. PBPK models for the prediction of in vivo performance of oral dosage forms. Eur J Pharm Sci. 2014;57:300–21.
  • Butler J, Hens B, Vertzoni M, Brouwers J, Berben P, Dressman J, et al. In vitro models for the prediction of in vivo performance of oral dosage forms: Recent progress from partnership through the IMI OrBiTo collaboration. Eur J Pharm Biopharm. 2019;136:70–83.